NO985917L - Reduksjon av kardiotoksisitet til antitumormiddel ved bruk av manganforbindelse - Google Patents

Reduksjon av kardiotoksisitet til antitumormiddel ved bruk av manganforbindelse

Info

Publication number: NO985917L
Authority: NO; Norway
Prior art keywords: cardiotoxicity; reduction; antitumor drug; manganese compound; reducing
Prior art date: 1996-06-24

Application number

NO985917A

Other languages

English (en)

Norwegian (no)

Other versions

NO985917D0 (no

Inventor

Robertson Towart

Jan Olof Gustav Karlsson

Per Jynge

Original Assignee

Nycomed Imaging As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-06-24

Filing date

1998-12-17

Publication date

1999-01-25

1998-12-17 Application filed by Nycomed Imaging As filed Critical Nycomed Imaging As

1998-12-17 Publication of NO985917D0 publication Critical patent/NO985917D0/no

1999-01-25 Publication of NO985917L publication Critical patent/NO985917L/no

Links

206010048610 Cardiotoxicity Diseases 0.000 title abstract 2
239000002246 antineoplastic agent Substances 0.000 title abstract 2
231100000259 cardiotoxicity Toxicity 0.000 title abstract 2
229940041181 antineoplastic drug Drugs 0.000 title 1
150000002697 manganese compounds Chemical class 0.000 title 1
PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
239000003814 drug Substances 0.000 abstract 2
229910052748 manganese Inorganic materials 0.000 abstract 2
239000011572 manganese Substances 0.000 abstract 2
229930012538 Paclitaxel Natural products 0.000 abstract 1
229940045799 anthracyclines and related substance Drugs 0.000 abstract 1
239000002738 chelating agent Substances 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
229910052751 metal Inorganic materials 0.000 abstract 1
239000002184 metal Substances 0.000 abstract 1
229960001592 paclitaxel Drugs 0.000 abstract 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
229940124597 therapeutic agent Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Inorganic Chemistry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Toxicology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Preventing Corrosion Or Incrustation Of Metals (AREA)
Manufacture And Refinement Of Metals (AREA)
Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Semiconductor Lasers (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

NO985917A 1996-06-24 1998-12-17 Reduksjon av kardiotoksisitet til antitumormiddel ved bruk av manganforbindelse NO985917L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9613182.6A GB9613182D0 (en)	1996-06-24	1996-06-24	Method
PCT/GB1997/001721 WO1997049390A1 (en)	1996-06-24	1997-06-24	Reduction of cardiotoxicity of an antitumor agent using manganese compound

Publications (2)

Publication Number	Publication Date
NO985917D0 NO985917D0 (no)	1998-12-17
NO985917L true NO985917L (no)	1999-01-25

Family

ID=10795775

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO985917A NO985917L (no)	1996-06-24	1998-12-17	Reduksjon av kardiotoksisitet til antitumormiddel ved bruk av manganforbindelse
NO985916A NO985916L (no)	1996-06-24	1998-12-17	Chelaterende midler og metallchelater for bruk i behandling av tilstander forÕrsaket av frie radikaler

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO985916A NO985916L (no)	1996-06-24	1998-12-17	Chelaterende midler og metallchelater for bruk i behandling av tilstander forÕrsaket av frie radikaler

Country Status (14)

Country	Link
US (2)	US6147094A (de)
EP (2)	EP0936915B1 (de)
JP (2)	JP4359651B2 (de)
CN (2)	CN1228703A (de)
AT (2)	ATE228361T1 (de)
AU (2)	AU720621B2 (de)
BR (1)	BR9709942A (de)
CA (2)	CA2259150A1 (de)
DE (2)	DE69717447T2 (de)
GB (1)	GB9613182D0 (de)
IL (1)	IL127733A0 (de)
NO (2)	NO985917L (de)
NZ (2)	NZ333315A (de)
WO (2)	WO1997049390A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69826528T2 (de) *	1997-12-23	2006-02-23	Amersham Health As	Stickstoffoxid freisetzende chelatbildner und ihre therapeutische verwendung
GB9727224D0 (en) *	1997-12-23	1998-02-25	Nycomed Imaging As	Method
KR20100075503A (ko)	1999-10-01	2010-07-02	디엠아이 바이오사이언시스, 인크	금속 결합 화합물 및 그의 용도
US7632803B2 (en)	1999-10-01	2009-12-15	Dmi Life Sciences, Inc.	Metal-binding compounds and uses therefor
US7592304B2 (en)	1999-10-01	2009-09-22	Dmi Life Sciences, Inc.	Metal-binding compounds and uses therefor
FR2823977B1 (fr)	2001-04-26	2006-12-01	Univ Rene Descartes	Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif
GB0117645D0 (en) *	2001-07-19	2001-09-12	Isis Innovation	Therapeutic stratergies for prevention and treatment of alzheimers disease
US20040038904A1 (en) *	2002-05-21	2004-02-26	Angela Ogden	Method of treating multiple sclerosis
FR2863892B1 (fr) *	2003-12-18	2007-05-11	Univ Paris Descartes	Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux
PT1744764E (pt)	2004-04-22	2012-08-30	Celator Pharmaceuticals Inc	Formulações lipossómicas de agentes antraciclina e análogos de citidina
BRPI0615265A8 (pt)	2005-08-31	2018-03-06	Abraxis Bioscience Llc	composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
KR101678865B1 (ko)	2007-12-14	2016-11-23	플레드파르마 에이비	암의 치료에 사용하기 위한 화합물들
WO2011004325A1 (en) *	2009-07-06	2011-01-13	Pledpharma Ab	Pharmaceutical compositions and therapeutic methods employing a combination of a manganese complex compound and a non-manganese complex form of the compound
HRP20200793T1 (hr)	2011-05-09	2020-10-16	Mayo Foundation For Medical Education And Research	Liječenje raka
AU2012364227B2 (en)	2012-01-05	2017-12-07	Egetis Therapeutics Ab	Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment
CA2917407C (en)	2012-10-01	2023-03-14	Mayo Foundation For Medical Education And Research	Complexes containing albumin-containing nanoparticles and antibodies to treat cancer
KR20150080616A (ko)	2012-11-02	2015-07-09	플레드파르마 에이비	암 치료 방법
CA2950926A1 (en)	2014-06-13	2015-12-17	Mayo Foundation For Medical Education And Research	Albumin-bound paclitaxel nanoparticle/rituximab complexes for treatment of cd20-expressing lymphomas
JP6600651B2 (ja)	2014-06-16	2019-10-30	マヨファウンデーションフォーメディカルエデュケーションアンドリサーチ	骨髄腫の治療
US9446148B2 (en)	2014-10-06	2016-09-20	Mayo Foundation For Medical Education And Research	Carrier-antibody compositions and methods of making and using the same
TW201707725A (zh)	2015-08-18	2017-03-01	美國馬友醫藥教育研究基金會	載體－抗體組合物及其製造及使用方法
TW201713360A (en)	2015-10-06	2017-04-16	Mayo Foundation	Methods of treating cancer using compositions of antibodies and carrier proteins
EP3399861A4 (de)	2016-01-07	2019-08-07	Mayo Foundation for Medical Education and Research	Verfahren zur behandlung von krebs mit interferon
US11351254B2 (en)	2016-02-12	2022-06-07	Mayo Foundation For Medical Education And Research	Hematologic cancer treatments
CA3018340A1 (en)	2016-03-21	2017-09-28	Mayo Foundation For Medical Education And Research	Methods for improving the therapeutic index for a chemotherapeutic drug
EP3432926A4 (de)	2016-03-21	2019-11-20	Mayo Foundation for Medical Education and Research	Verfahren zur verminderung der toxizität eines chemotherapeutikums
US10618969B2 (en)	2016-04-06	2020-04-14	Mayo Foundation For Medical Education And Research	Carrier-binding agent compositions and methods of making and using the same
EP3506950A1 (de)	2016-09-01	2019-07-10	Mayo Foundation for Medical Education and Research	Gegen t-zell-karzinome gerichtete verfahren und zusammensetzungen
JP7525999B2 (ja)	2016-09-01	2024-07-31	マヨファウンデーションフォーメディカルエデュケーションアンドリサーチ	キャリアー－ｐｄ－ｌ１結合剤組成物及び癌を処置する為にそれを使用する方法
CN109843924A (zh)	2016-09-06	2019-06-04	梅约医学教育与研究基金会	治疗表达pd-l1的癌症的方法
RU2756892C2 (ru)	2016-09-06	2021-10-06	Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч	Композиции с паклитакселом, альбумином и связывающим средством и способы их применения и получения
EP3509635A1 (de)	2016-09-06	2019-07-17	Vavotar Life Sciences LLC	Verfahren zur behandlung von dreifach negativem brustkrebs unter verwendung von zusammensetzungen aus antikörpern und trägerproteinen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES444380A1 (es) *	1976-01-16	1977-06-16	Gosalvez Mario	Un procedimiento para preparar derivados metalicos antraci- clinicos.
US4842845A (en) *	1987-05-08	1989-06-27	Salutar, Inc.	Radioactive metal chelates for dipyridoxyl phosphate
US5223243A (en) *	1987-05-08	1993-06-29	Salutar, Inc.	Dipyridoxyl phosphate chelating compound intermediates useful as NMRI contrast agents
US4935518A (en) *	1987-05-08	1990-06-19	Salutar, Inc.	Manganese(II), chelate contrast agents derived from N,N'-bis-(pyridoxal ethylene diamine-N,N')-diacetic acid and derivatives thereof
US6204259B1 (en) *	1993-01-14	2001-03-20	Monsanto Company	Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide

1996
- 1996-06-24 GB GBGB9613182.6A patent/GB9613182D0/en active Pending
1997
- 1997-06-24 AT AT97928368T patent/ATE228361T1/de not_active IP Right Cessation
- 1997-06-24 EP EP97928369A patent/EP0936915B1/de not_active Expired - Lifetime
- 1997-06-24 NZ NZ333315A patent/NZ333315A/xx unknown
- 1997-06-24 IL IL12773397A patent/IL127733A0/xx unknown
- 1997-06-24 JP JP50255798A patent/JP4359651B2/ja not_active Expired - Lifetime
- 1997-06-24 WO PCT/GB1997/001721 patent/WO1997049390A1/en not_active Ceased
- 1997-06-24 DE DE69717447T patent/DE69717447T2/de not_active Expired - Lifetime
- 1997-06-24 CA CA002259150A patent/CA2259150A1/en not_active Abandoned
- 1997-06-24 CA CA002258299A patent/CA2258299A1/en not_active Abandoned
- 1997-06-24 DE DE69716104T patent/DE69716104T2/de not_active Expired - Lifetime
- 1997-06-24 CN CN97197438A patent/CN1228703A/zh active Pending
- 1997-06-24 BR BR9709942A patent/BR9709942A/pt not_active Application Discontinuation
- 1997-06-24 WO PCT/GB1997/001722 patent/WO1997049409A1/en not_active Ceased
- 1997-06-24 NZ NZ333357A patent/NZ333357A/xx unknown
- 1997-06-24 AU AU32689/97A patent/AU720621B2/en not_active Ceased
- 1997-06-24 CN CN97197429A patent/CN1228694A/zh active Pending
- 1997-06-24 EP EP97928368A patent/EP0910360B1/de not_active Expired - Lifetime
- 1997-06-24 AU AU32688/97A patent/AU720570B2/en not_active Ceased
- 1997-06-24 AT AT97928369T patent/ATE225178T1/de not_active IP Right Cessation
- 1997-06-24 JP JP50255898A patent/JP4162263B2/ja not_active Expired - Lifetime
1998
- 1998-12-17 NO NO985917A patent/NO985917L/no not_active Application Discontinuation
- 1998-12-17 US US09/213,246 patent/US6147094A/en not_active Expired - Lifetime
- 1998-12-17 NO NO985916A patent/NO985916L/no not_active Application Discontinuation
- 1998-12-17 US US09/213,290 patent/US6258828B1/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
NO985916D0 (no)	1998-12-17
EP0910360B1 (de)	2002-11-27
BR9709942A (pt)	1999-08-10
AU720570B2 (en)	2000-06-08
AU3268997A (en)	1998-01-14
NZ333357A (en)	2000-08-25
US6147094A (en)	2000-11-14
NO985916L (no)	1999-01-25
US6258828B1 (en)	2001-07-10
JP4359651B2 (ja)	2009-11-04
NO985917D0 (no)	1998-12-17
JP4162263B2 (ja)	2008-10-08
ATE225178T1 (de)	2002-10-15
IL127733A0 (en)	1999-10-28
EP0936915B1 (de)	2002-10-02
AU720621B2 (en)	2000-06-08
NZ333315A (en)	2000-07-28
AU3268897A (en)	1998-01-14
WO1997049409A1 (en)	1997-12-31
CA2258299A1 (en)	1997-12-31
GB9613182D0 (en)	1996-08-28
ATE228361T1 (de)	2002-12-15
DE69717447T2 (de)	2003-09-11
JP2000513351A (ja)	2000-10-10
DE69716104D1 (de)	2002-11-07
EP0936915A1 (de)	1999-08-25
JP2000514044A (ja)	2000-10-24
CN1228694A (zh)	1999-09-15
CA2259150A1 (en)	1997-12-31
EP0910360A1 (de)	1999-04-28
DE69717447D1 (de)	2003-01-09
CN1228703A (zh)	1999-09-15
WO1997049390A1 (en)	1997-12-31
DE69716104T2 (de)	2003-05-28

Legal Events

Date	Code	Title	Description
2003-02-17	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO985917D0 (no)	1998-12-17	Reduksjon av kardiotoksisitet til antitumormiddel ved bruk av manganforbindelse
WO2002056912A3 (en)	2003-05-22	Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
EP0911039A3 (de)	2003-06-25	Wirkstoff-Harzkomplexe stabilisiert mit Chelatbildner
EP2261200A3 (de)	2010-12-29	Modifizierte Formen von pharmakologisch aktiven Agenzien und deren Verwendung
ATE339406T1 (de)	2006-10-15	Chinazoline verbindungen als heilmittel
WO2002013873A3 (en)	2003-05-01	P97-active agent conjugates and their methods of use
IL162214A0 (en)	2005-11-20	Pyridine derivatives and pharmaceutical compositions containing the same
WO2000066093A3 (en)	2001-01-25	Combined preparations comprising morpholine anthracyclines and anticancer agent
DE60121440D1 (de)	2006-08-24	Krebsbehandlung zusammensetzung, welche ein antineoplastisches mittel und pde4 inhibitor enthält
WO2003041736A3 (en)	2004-03-11	Method for the treatment of cardiotoxicity induced by antitumor compounds
HUP0401501A3 (en)	2012-02-28	Treating or preventing vascular inflammation using pharmaceutical compositions containing sterol absorption inhibitor(s)
WO1998036730A3 (de)	1998-10-22	Zubereitungen für die behandlung von rosacea
EP1545479A4 (de)	2007-10-24	Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren
DK0810883T3 (da)	2002-11-11	Konjugat indeholdende DTPA og albumin til individuel dosering af lægemidler
MXPA02005045A (es)	2003-09-25	Preparaciones farmaceuticas que contiene agentes citostaticos y aceptores de electrones para el tratamiento de cancer.
UY26171A1 (es)	2000-12-29	Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
ES2192420T3 (es)	2003-10-01	Utilizacion de una composicion farmaceutica que comprende un agente anticanceroso y al menos un peptido.
IL141645A0 (en)	2002-03-10	Use of methoxymorpholino doxorubicin for the treatment of a liver tumor
WO2002038566A3 (en)	2002-09-12	Carbene porphyrins and carbene porphyrinoids for use in medical diagnosis and treatment
WO2001000189A3 (de)	2001-08-02	Kombination von mtp-inhibitoren und stoffwechselbeeinflussenden wirkstoffen und ihre verwendung in arzneimitteln
DE69818492D1 (en)	2003-10-30	7-methylthiooxomethyl- und 7-methylthiodioxomethyl-paclitaxele
WO2003020371A3 (en)	2003-07-17	Potentiator composition comprising a terpene for enhancing a therapeutical effect of antitumoral agents in the treatment of cancer
ZA989356B (en)	1998-11-16	Pharmaceutical preparations
DE60003189D1 (de)	2003-07-10	Synergistische zusammensetzung, die daunorubicin derivate und antimetabolite enthält
MX9800697A (es)	1998-09-30	Uso de glicosidos de calendula para el tratamiento de psoriasis.